4 January 2024
Board change
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announces that following completion of his nine-year tenure, Erik Engstrom stepped down from the Board on 31 December 2023.
The Board would like to thank Erik for his commitment and contribution to the Board and the Company.
Enquiries
| Investors / Analysts Andrew Swift
|
+44 (0) 1923 477433 |
| Media Charles Reynolds
|
+44 (0) 1923 477314 |
| Susan Gilchrist / Ayesha Bharmal | +44 (0) 20 7404 5959
|
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 19,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2022. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.